Pharma Patent Expansion Buried in 'Affordable Prescriptions' Bill

What it does

This bill amends patent law to allow pharmaceutical companies holding patents on reference biological products (like biologics) to sue generic/biosimilar competitors and assert up to 20 patents per lawsuit—but with restrictions: no more than 10 patents issued after a specified date, and patents must meet certain criteria (claiming the product itself, listed on the FDA patent list, or filed more than 4 years after approval). Courts can increase this limit if the generic applicant withholds required information or if other good cause exists. The effect is to strengthen patent holders' litigation power against biosimilar entrants while creating procedural hurdles for generics to clear.

Why we flagged it

The bill's core function is to expand patent litigation rights for brand-name biologic manufacturers against biosimilar competitors. Despite the title's consumer-friendly framing ('Affordable Prescriptions'), the operative mechanism restricts generic competition and extends monopoly periods—the opposite of affordability.

What the text implies

• The 20-patent assertion limit per lawsuit, combined with the ability to increase it for 'good cause,' creates a litigation burden that may deter smaller generic manufacturers from challenging patents, even weak ones, due to legal costs.
• The provision allowing courts to increase patent limits if the generic applicant 'fails to provide information' shifts burden of proof and may chill legitimate generic development by creating ambiguity about what information is 'required.'
• By restricting which patents can be asserted (e.g., excluding those filed >4 years after approval or claiming manufacturing methods not used by the brand), the bill creates a complex carve-out that may be difficult for courts to apply consistently, leading to unpredictable litigation outcomes.
• The bill does not cap damages or litigation costs, meaning even if a generic wins on the merits, the cost of defending against 20 simultaneous patent claims may make market entry economically unviable, effectively extending monopoly periods without formal patent extension.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

This bill extends and strengthens patent protections for brand-name biologics, making it harder and more expensive for biosimilar (generic biologic) competitors to enter the market. Delayed generic competition means higher drug prices for patients and longer monopoly periods for patent holders. Citizens bear the cost through higher out-of-pocket expenses and delayed access to affordable alternatives.

Who stands to gain

• brand-name biologic pharmaceutical manufacturers
• patent holders in the biologics sector
• pharmaceutical litigation firms

Named in the bill

35 USC Section 271, Public Health Service Act Section 351, FDA, reference product sponsors, biosimilar applicants, biological products

Where it stands

3 cosponsors: 2 Democrats, 1 Republicans.

• Mar 13, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• Mar 13, 2025 — Referred to Senate Committee on the Judiciary · Congress.gov: “Read twice and referred to the Committee on the Judiciary”
• Apr 3, 2025 — Reported out of committee · Congress.gov: “Committee on the Judiciary. Ordered to be reported with amendments favorably”
• Jul 21, 2026 — Passed the Senate · Congress.gov: “Passed Senate with amendments by Unanimous Consent. (consideration: CR S4198-4199; text: CR S4199)”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

35 lobbying clients named this bill on 54 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $35,255,337 in lobbying spend. A filing names 14 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 98% of bills with at least one filing.

John Cornyn, the sponsor, reported $2,042,484 in PAC receipts in the 2026 cycle. $29,500 of that came from 4 PACs tied to these lobbying clients.

• Pharmaceutical Research and Manufacturers of America — $15,770,000 on 2 filings
• Pharmaceutical Care Management Association — $3,282,990 on 1 filing
• Amgen Inc — $2,440,000 on 1 filing
• Blue Cross and Blue Shield Association — $2,430,000 on 2 filings
• Biotechnology Innovation Organization — $2,360,000 on 1 filing

Lobbying Disclosure Act filings through Jul 22, 2026. A filing shows who paid to lobby on a bill it names, not what changed.